Friday, April 24, 2020 Daily Archives

Emergent to produce J&J COVID-19 vaccine in $135m contract

by

As it prepares to advance its COVID-19 vaccine candidate, J&J has contracted CDMO Emergent Biosolutions and reserved large-scale capacity at its site in Maryland. In its efforts to tackle the novel coronavirus (SARS-CoV-2), Johnson & Johnson (J&J) began working on a vaccine candidate in early January and last month identified a lead COVID-19 vaccine candidate and two backups. To prepare for trials and future approval, the firm has inked a deal with contract development and manufacturing organization (CDMO) Emergent BioSolutions…

April 24, 2020

Eli Lilly and AbCellera begin GMP manufacture of potential COVID-19 MAb

by

Eli Lilly has three therapy programs attempting to combat COVID-19 but says its monoclonal antibody partnership with AbCellera is the most significant. In March, Eli Lilly inked a deal to codevelop antibody products for the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus, using AbCellera’s pandemic response platform. While discussing its first quarter 2020 results, Lilly described the collaboration as the “most significant program†of its active therapeutic programs it is pursuing against COVID-19 and…

April 24, 2020

COVID-19 an opportunity for outsourcing sector, say leading CDMOs

by

COVID-19 has increased demand for outsourcing but it is too early to tell what long term impact the pandemic will have, say leading CDMOs. Lonza has received more than 40 inquiries about COVID-19 related projects, says CEO Albert Baehny. He told analysts the pandemic “has already offered some new and important opportunities, which are currently under review.†He added, “Inevitably we cannot engage and collaborate in all of those projects. Instead, we are focusing our efforts on selected key development…

April 24, 2020